Furthermore, the therapeutic superiority of PRMT3 inhibition in conjunction with classical therapies was corroborated by cell‐derived xenograft (CDX) and patient‐derived xenograft (PDX) tumor model results. The gene discussed is PRMT3; the disease is neoplasm.